ELEV实时信号 | 通过Getagraph.com最大化利润

购买 107886 min ago

@ $2.71

发出时间: 14 Feb 2024 @ 23:56

回报率: 33.58%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -6.62 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:02):

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States...

Stats
今日成交量	37 603.00
平均成交量	1.16M
市值	176.12M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.210 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.70
ATR14	$0.0130 (0.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-16	Ferra Joseph J Jr	Buy	12 562	Common Stock
2024-03-16	Ferra Joseph J Jr	Sell	4 773	Common Stock
2024-03-16	Ferra Joseph J Jr	Sell	12 562	Restricted Stock Unit
2024-02-29	Sandler Alan B.	Buy	55 000	Stock Option (Right to Buy)
2024-02-29	Cherrington Julie M	Buy	55 000	Stock Option (Right to Buy)

INSIDER POWER
75.56
Last 96 transactions
Buy: 15 904 291 \| Sell: 39 693 676

音量相关性

長: 0.10 (neutral)

短: 0.36 (neutral)

Signal:(44.062) Neutral

Elevation Oncology, Inc. 相关性

10 最正相关
ASLN	0.917
HUGE	0.917
MOTNU	0.917
BCYP	0.912
KBAL	0.912
INTA	0.902
LTRY	0.899
VRCA	0.896
AZRX	0.896
MKGI	0.895

10 最负相关
STIM	-0.911
CARA	-0.909
CBLI	-0.906
CPTN	-0.906
FMBH	-0.904
ALHC	-0.903
ATHN	-0.902
CSTR	-0.898
BOWX	-0.897
NRIM	-0.896

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Elevation Oncology, Inc. 相关性 - 货币/商品

-0.57
( weak negative )

-0.51
( weak negative )

0.00
( neutral )

-0.61
( weak negative )

0.51
( weak )

0.74
( moderate )

Elevation Oncology, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-39 000.00 (0.00 %)
EPS:	$-1.340

FY	2023
营收:	$0
毛利润:	$-39 000.00 (0.00 %)
EPS:	$-1.340

FY	2022
营收:	$0
毛利润:	$-27 000.00 (0.00 %)
EPS:	$-4.09

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.386

Financial Reports:

No articles found.

Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.